Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model
| Autor: | Ralf A. Linker, Seray Demir, Ralf Gold, Kalliopi Pitarokoili |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Encephalomyelitis Autoimmune Experimental CD52 T-Lymphocytes medicine.medical_treatment Immunology Humanized antibody medicine.disease_cause Autoimmunity Mice 03 medical and health sciences 0302 clinical medicine Immune system Neurotrophic factors Animals Immunologic Factors Immunology and Allergy Medicine Alemtuzumab Mice Knockout biology business.industry Brain-Derived Neurotrophic Factor Macrophages Experimental autoimmune encephalomyelitis Immunotherapy medicine.disease Mice Inbred C57BL Neuroprotective Agents 030104 developmental biology Spinal Cord Neurology biology.protein Neurology (clinical) Antibody business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Neuroimmunology. 328:78-85 |
| ISSN: | 0165-5728 |
| Popis: | The murine anti-CD52 antibody, an equivalent of the humanized antibody alemtuzumab, which is successfully used in the treatment of multiple sclerosis, was used to explore a potential neuroprotective effect driven by immune cell derived brain-derived neurotrophic factor (BDNF). Therefore, lineage specific constitutive knock-out mice with a BDNF deficiency in T cells and macrophages were used and compared to treated wildtype mice. Neither therapeutic nor preventive application of the murine anti-CD52 antibody in an animal model of multiple sclerosis, the MOG35-55 EAE, revealed a beneficial contribution of immune cell derived BDNF to the disease outcome. Furthermore, preventive application of the murine anti-CD52 antibody worsened the clinical EAE disease course and could only be overcome by a prolonged recovery phase after treatment and before disease induction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect